The Evaluation of Interactions Between Multiple Intrinsic and Extrinsic Factors Reported in Labeling for FDA-Approved...

Area of Science:

• Pharmacology and Drug Development
• Clinical Pharmacology
• Regulatory Science

Background:

• Drug development requires evaluating pharmacokinetics (PK) and pharmacodynamics to understand how intrinsic and extrinsic factors influence drug exposure and response.
• Accounting for interindividual variability is crucial for safe and effective dosing in diverse patient populations.
• However, assessing the combined effects of multiple co-occurring factors remains a significant challenge.

Purpose of the Study:

• To analyze US Food and Drug Administration (FDA) drug labeling for therapeutic products approved between 2019 and 2023.
• To determine if intrinsic and extrinsic factors are evaluated simultaneously in drug labeling.
• To understand how these factors influence prescribing recommendations for complex patient populations.

Main Methods:

• Analysis of 227 drug labelings approved by the FDA's Center for Drug Evaluation and Research (CDER) from 2019 to 2023.
• Characterization of factors including pharmacogenomics (PGx), renal and hepatic function, age, pregnancy, body weight, comorbidities, and drug-drug interactions (DDIs).
• Assessment of whether factors were considered independently or simultaneously to influence prescribing information.

Main Results:

• 93% of drug labelings assessed more than one factor independently, while only 2.6% evaluated the combined influence of two factors.
• Commonly assessed single factors included age (78.9%), renal impairment (74.4%), and PK DDIs (70.0%).
• Only six labelings addressed simultaneously occurring factors, with four examining the interaction between PGx and PK DDIs.

Conclusions:

• A significant gap exists in the evaluation of co-occurring intrinsic and extrinsic factors within current drug labeling practices.
• Current drug labeling predominantly focuses on single factors, limiting guidance for patients with multiple co-existing conditions or taking multiple medications.
• There is a critical need for integrated approaches in drug development to comprehensively assess combined factors, improving clinical decision-making for complex patient populations.